Metabolic Disease Has a Greater Effect on the Health of Our Society Than Cancer
The 3rd World Summit on Metabolic Diseases explores the latest findings and treatments for Metabolic Diseases
Monrovia, CA, October 15, 2007 --(PR.com)-- Metabolic syndrome, which combines glucose intolerance, hyperlipidemia, obesity, and hypertension, is a rapidly rising condition in our global society. This coalescence of unfavorable health factors affects at least one quarter of the US population and is associated with a marked increase in risk of cardiovascular disease.
Important statistics:
· Annual dollars spent on obesity: $44 billion/year
· Annual dollars spent on diabetes: $98 billion/year
· An estimated 47 million U.S. residents have the metabolic syndrome.
· The age-adjusted prevalence of the metabolic syndrome for adults is 23.7 percent.
· 15-20 drugs in clinical trials for obesity
· 55 drugs for diabetes
An increasing effort is being made to better understand and find new innovative approaches to treating these problems. We are seeing growing endeavors being made to find pharmaceutical solutions to prevent and reverse the Metabolic Syndrome. This Meeting is devoted to better understanding new options to deal this condition. This year we will be focusing on emerging approaches to treat the Metabolic Syndrome, including modulators of the mitochondrion and on steroid biosynthesis and we will hear about new agents in the battle against obesity. A special feature this year will be a Symposium on The New World of Insulin. We will devote our attention to insulin treatment as well as new approaches to Beta Cell preservation and regeneration.
Marc Rendell, the conference chairman states, “The Metabolic Summit is in its third year. The conference focuses on areas not covered in other major Meetings. We proudly bring together experts from both the academic and pharmaceutical world in our efforts to highlight major issues. This year we are featuring a Symposium on The new World of Insulin as well as a presentation of new approaches to The Metabolic Syndrome.” The main goal of the summit is to encourage the free flow of information among our participants.
Featured discussions and thought leaders:
· The History of Insulin: How Far Have We Come! (?), Jeffrey A. Jackson, MD CDE, Medical Advisor—USMD Diabetes, Eli Lilly and Company
· Transplantation and Beyond, Aaron I. Vinik, M.D., Ph.D. , Professor of Internal Medicine; Director, Strelitz Diabetes Institute
· The Future Regulatory Environment for Metabolic Drugs—Sorting through the Good, the Bad, and the Ugly., G. Alexander Fleming, President and CEO, Kinexum LLC
· Modulation of the Thyroid Hormone Receptor to Attack the Metabolic Syndrome, John Baxter, Professor of Medicine University of California, San Francisco
· 1F0 ATPase that Shows its Importance in Ischemia, Gary Grover, Director Pharmacology, Eurofins-PSL.
· Patients with Severe Mental Illness seem to have a Season Ticket for Diabetes and CVD Risk Factors. Why the Lack of Interest in Prevention, Chris Bushe, MB BS, Head of CNS Medical Liaison and Senior Clinical Research Physician Eli Lilly and Company Limited
· Revisiting Ponce De Leon: Mitochondria and the Metabolic Diseases of Aging, Charles Alexander, Senior Director, Global Outcomes Research & HTA , Merck
· Regulation of Skeletal Muscle Oxidative Capacity and Insulin Signaling by the Mitochondrial Protease PARL, Anthony Civitarese, Head of Skeletal Muscle Metabolism, Pennington Biomedical Research Center
Speakers will focus on advances for:
· Diabetes
· Insulin
· Cardiovascular Diseases
· Obesity
· Mitochondrial Function
At GTCbio conferences delegates are high level executives from pharmaceuticals, biotech companies and academia.
About The 3rd Metabolic Diseases World Summit:
The 3rd Metabolic Diseases World Summit taking place on November 1-2 in San Diego, CA is devoted to better understanding new options in dealing with this condition. Speakers from both academia and industry will focus on the advances of treatments for Metabolic Diseases and how they relate to Insulin, Diabetes, Obesity, Cardiovascular Disease and Mitochondrial Function.
For more information on this conference including a detailed agenda, exhibitor opportunities and registration go to: http://www.gtcbio.com/conference/conferenceDetails.aspx?id=9
About GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. The companies’ goals are to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community. GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
For more information contact: Vivian Juter Frankel
Senior Conference Producer
626-256-6405 x 105
vivian.frankel@gtcbio.com
http://www.gtcbio.com
GTCbio
434 W Foothill Blvd.
Monrovia, CA 91016
###
Important statistics:
· Annual dollars spent on obesity: $44 billion/year
· Annual dollars spent on diabetes: $98 billion/year
· An estimated 47 million U.S. residents have the metabolic syndrome.
· The age-adjusted prevalence of the metabolic syndrome for adults is 23.7 percent.
· 15-20 drugs in clinical trials for obesity
· 55 drugs for diabetes
An increasing effort is being made to better understand and find new innovative approaches to treating these problems. We are seeing growing endeavors being made to find pharmaceutical solutions to prevent and reverse the Metabolic Syndrome. This Meeting is devoted to better understanding new options to deal this condition. This year we will be focusing on emerging approaches to treat the Metabolic Syndrome, including modulators of the mitochondrion and on steroid biosynthesis and we will hear about new agents in the battle against obesity. A special feature this year will be a Symposium on The New World of Insulin. We will devote our attention to insulin treatment as well as new approaches to Beta Cell preservation and regeneration.
Marc Rendell, the conference chairman states, “The Metabolic Summit is in its third year. The conference focuses on areas not covered in other major Meetings. We proudly bring together experts from both the academic and pharmaceutical world in our efforts to highlight major issues. This year we are featuring a Symposium on The new World of Insulin as well as a presentation of new approaches to The Metabolic Syndrome.” The main goal of the summit is to encourage the free flow of information among our participants.
Featured discussions and thought leaders:
· The History of Insulin: How Far Have We Come! (?), Jeffrey A. Jackson, MD CDE, Medical Advisor—USMD Diabetes, Eli Lilly and Company
· Transplantation and Beyond, Aaron I. Vinik, M.D., Ph.D. , Professor of Internal Medicine; Director, Strelitz Diabetes Institute
· The Future Regulatory Environment for Metabolic Drugs—Sorting through the Good, the Bad, and the Ugly., G. Alexander Fleming, President and CEO, Kinexum LLC
· Modulation of the Thyroid Hormone Receptor to Attack the Metabolic Syndrome, John Baxter, Professor of Medicine University of California, San Francisco
· 1F0 ATPase that Shows its Importance in Ischemia, Gary Grover, Director Pharmacology, Eurofins-PSL.
· Patients with Severe Mental Illness seem to have a Season Ticket for Diabetes and CVD Risk Factors. Why the Lack of Interest in Prevention, Chris Bushe, MB BS, Head of CNS Medical Liaison and Senior Clinical Research Physician Eli Lilly and Company Limited
· Revisiting Ponce De Leon: Mitochondria and the Metabolic Diseases of Aging, Charles Alexander, Senior Director, Global Outcomes Research & HTA , Merck
· Regulation of Skeletal Muscle Oxidative Capacity and Insulin Signaling by the Mitochondrial Protease PARL, Anthony Civitarese, Head of Skeletal Muscle Metabolism, Pennington Biomedical Research Center
Speakers will focus on advances for:
· Diabetes
· Insulin
· Cardiovascular Diseases
· Obesity
· Mitochondrial Function
At GTCbio conferences delegates are high level executives from pharmaceuticals, biotech companies and academia.
About The 3rd Metabolic Diseases World Summit:
The 3rd Metabolic Diseases World Summit taking place on November 1-2 in San Diego, CA is devoted to better understanding new options in dealing with this condition. Speakers from both academia and industry will focus on the advances of treatments for Metabolic Diseases and how they relate to Insulin, Diabetes, Obesity, Cardiovascular Disease and Mitochondrial Function.
For more information on this conference including a detailed agenda, exhibitor opportunities and registration go to: http://www.gtcbio.com/conference/conferenceDetails.aspx?id=9
About GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. The companies’ goals are to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community. GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
For more information contact: Vivian Juter Frankel
Senior Conference Producer
626-256-6405 x 105
vivian.frankel@gtcbio.com
http://www.gtcbio.com
GTCbio
434 W Foothill Blvd.
Monrovia, CA 91016
###
Contact
GTCbio
Vivian Frankel
626-256-6405
www.gtcbio.com
Vivian Frankel
626-256-6405
www.gtcbio.com
Contact
Categories